University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Papers in Veterinary and Biomedical Science

Veterinary and Biomedical Sciences,
Department of

2010

Method for identification of Virulence Determinants
Raul G. Barletta
Lincoln, NE, rbarletta1@unl.edu

Beth Harris
Lincoln, NE

Follow this and additional works at: https://digitalcommons.unl.edu/vetscipapers
Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cell and Developmental
Biology Commons, Immunology and Infectious Disease Commons, Medical Sciences Commons,
Veterinary Microbiology and Immunobiology Commons, and the Veterinary Pathology and Pathobiology
Commons

Barletta, Raul G. and Harris, Beth, "Method for identification of Virulence Determinants" (2010). Papers in
Veterinary and Biomedical Science. 361.
https://digitalcommons.unl.edu/vetscipapers/361

This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and
Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

US007740867B2

(12) United States Patent

(10) Patent No.:

Barletta et al.

US 7,740,867 B2

(45) Date of Patent:

Jun. 22, 2010

(54) METHOD FOR IDENTIFICATION OF

WO

WO99.05.168 A1

2/1999

VIRULENCE DETERMINANTS

WO

WO99, 10475 A2

3, 1999

(75) Inventors: Raul G. Barletta, Lincoln, NE (US); N.
Beth Harris, Lincoln, NE (US)
(73) Assignee: Board of Regents of the University of
Nebraska, Lincoln, NE (US)
(*) Notice:

Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: 11/945,770
(22) Filed:

Nov. 27, 2007

(65)

Prior Publication Data
US 2008/O166321 A1

Immunol 14:9 (2007). 1078-1083.

Jul. 10, 2008

Related U.S. Application Data
(62) Division of application No. 09/759,287, filed on Jan.
11, 2001, now abandoned.
(60) Provisional application No. 60/175,433, filed on Jan.
11, 2000.

(51) Int. Cl.
A6 IK 39/02

(2006.01)

A6 IK 39/04
A6 IK 49/00

(2006.01)
(2006.01)

Balasubramanian et al., Allelic Exchange in Mycobacterium tuber
culosis with Long Linear Recombination Substrates, J. Bacter. Jan.
1996, pp. 273-79, vol., 178, No. 1, Amer. Soc, Microb., USA.
Bardarov et al., Conditionally replicating mycobacteriophages: A
system for transposon delivery to Mycobacterium tuberculosis, Proc.
Natl. Acad. Sci., Sep. 1997, pp. 10961-10966, vol. 94, Natl. Acad.
Sci., USA.

Beaucage et al., Deoxynucleoside Phosphoramidites-A New Class
Of Key Intermediates For Deoxypolycucleotide Synthesis, Tet. Let.
1981, pp. 1859-1862, vol. 22, No. 20.
Bermudez et al., Isolation of two subpopulations of Mycobacterium
avium within human microphages, FEMS Micro. Let., p. 19-26, vol.
178, Elsevier Sciences.

Cáceres et al., Overexpression of the D-Alanine Racemase Gene
Confers Resistance to D-Cycloserine in Mycobacterium smegmatis,

(52) U.S. Cl. ...................... 424/234.1; 424/9.1; 424/9.2:
424/93.1; 424/93.2; 424/184.1; 424/248.1;
424/278.1; 424/823; 435/220.1; 435/.440;
435/.441; 435/442:435/.444; 435/466; 435/866;
514/2

(58) Field of Classification Search .................. 424/9.1,
424/9.2, 93.1, 93.2, 184.1, 234.1, 248.1,
424/278.1, 823; 435/220.1, 440, 441, 442,
435/443, 444, 466,866; 514/2
See application file for complete search history.

J.Micro.,
Bacter.USA.
Aug. 1997, pp. 5046-5055, Vol. 179, No. 16, Amer. Soc.

Camphausen et al. A glycolipid antigen specific to Mycobacterium
paratuberculosis: Structure and antigenicity, Proc. Natl. Acad. Sci.,
May 1985, pp. 3068-3072, vol. 82.
Cavalignac et al., Construction and Screening of Mycobacterium
paratuberculosis insertional mutant libraries, Arch. Microbiol., 2000,
pp. 229-231, vol. 173.
Cirillo et al., A Novel Transposon Trap for Mycobacteria: Isolation
and Characterization of IS1096, J. Bacter. Dec. 1991, pp. 7772
7780, vol. 173, Amer. Soc. Microb., USA.

References Cited

Cirillo et al., Interaction of Mycobacterium avium with Environmen
tal Amoebae Enhances Virulence, Infec. and Immun., Sep. 1997, pp.

U.S. PATENT DOCUMENTS

Cocito et al., Paratuberculosis, Clin. Microb. Reviews, Jul. 1994, pp.

(56)

4,341,761 A
4,399,121 A
4.427,783 A
4,444,887 A

7, 1982 Ganfield et al.
8, 1983 Albarella et al.
1, 1984 Newman et al.

4, 1984 Hoffmann

4.466.917 A

8/1984 Nussenzweig et al.

4472,500 A

9, 1984 Milstein et al.

4,491,632 A
4493,890 A
4,683, 195
4,683.202
4,800,159
4,965,188

OTHER PUBLICATIONS

Woo, S-R. etal. ATP release by infected bovine monocytes increases
the intracellular survival of Mycobacterium avium subsp,
paratuberculosis. Comp Immunol Microbiol Infect Dis (2008),
doi:10.1016/j.cimid.2007.11.003.
Woo, S-R., et al. Life and death in bovine monocytes: the fate of
Mycobacterium avium subsp. paratuberculosis. Microbial Pathogen
esis 43 (2007) 106-113.
Woo, S-R. etal. Bovine monocytes and a macrophage cell line differ
in their ability to phagocytose and Support the intracellularr Survival
of Mycobacterium avium subsp. paratuberculosis. Vet. Immunol.
Immunpathol 110 (2006) 109-120s.
Woo, S-R., et al. Extracellular ATP Is Cytotoxic to Mononuclear
Phagocytes but Does Not Induce Killing of Intracellular
Mycobacterium avium subsp. paratuberculosis. Clin Vaccine

A
A
A
A

5,783,386 A

6,095,549 A

1, 1985 Wands et al.
1, 1985 Morris

7, 1987
7, 1987
1, 1989
10, 1990

Mullis et al.
Mullis
Mullis et al.
Mullis et al.

3759-3767, vol. 65, No. 9, Amer. Soc. Microb., USA.
328-345, vol. 7, No. 3, Amer. Soc. Microb., USA.
Collins, Paratuberculosis diagnostics; We created the tests, now how
do we use them?, Proc. Fifih Intl. Colloq. Paratuberculosis, Chiodini
et al., eds. Intl. Assoc. for Paratuberculosis, 1997, pp. 232-241.

(Continued)
Primary Examiner Rodney P. Swartz
(74) Attorney, Agent, or Firm—Stinson Morrison Hecker
LLP

(57)

ABSTRACT

7/1998 Jacobs, Jr. et al.

Disclosed are methods for the determination of virulence

8, 2000 Pelicic et al.

determinants in bacteria and in particular bacteria of the

FOREIGN PATENT DOCUMENTS

genus Mycobacterium. Also disclosed are compositions and

methods for stimulating an immune response in an animal

O 812918 A2

12/1997

using bacteria and virulence determinants identified by the

WO

WO92,22326 A1

12, 1992

methods of the present invention.

WO

WO95/03417 A2

2, 1995

WO

WO99,02670 A1

1, 1999

EP

10 Claims, 2 Drawing Sheets

US 7,740,867 B2
Page 2
OTHER PUBLICATIONS

Collins et al., Herd prevalence and geographic distribution of, and
risk factors for, bovine paratuberculosis in Wisconsin, J. Amer. Vet.
Med. Assoc., Feb. 1994, pp. 636-641, vol. 204, No. 4.
Ellingson et al., Identification of a gene unique to Mycobacterium
avium subspecies paratuberculosis and application to diagnosis of
paratuberculosis, Mol. Cell. Probes, 1998, pp. 133-142, vol. 12,
Academic Press, USA.

El-Zaatari et al., Characterization of a Specific Mycobacterium
paratuberculosis Recombinant Clone Expressing 35,000-Molecular
Weight Antigen and Reactivity, with Sera from Animals with Clinical
and Subclinical Johne's Dsease, J. Clin. Microb. Jul. 1997, pp.
1794-1799, vol. 35, No. 7, Amer. Soc. Microb., USA.

Foley-Thomas et al., Phage infection, transfection and transforma
tion of Mycobacterium avium complex and Mycobacterium
paratuberculosis, 1995, pp. 1173-1181, vol. 141.
Green et al., Sequence and characteristics of IS900, an insertion
element identified in a human Crohn's disease Isolate of

Mycobacterium paratuberculosis, Nucl., Acids. Res, 1989, pp. 9063
9073, vol. 17, No. 22, IRL Press.

Guateli et al., Isothermal, in vitro amplification of nucleic acids by a
multienzyme reaction modeled after refroviral replication, Proc.
Natl. Acad. Sci., Mar. 1990, pp. 1874-1878, vol. 87, Biochem., USA.
Guilhot et al., Efficient Transposition in Mycobacteria: Construction
of Mycobacterium smegmatis Insertional Mutant Libraries, Jan.
1994, pp. 535-539, vol. 176, No. 2, Amer. Soc. Microb, USA.
Gunnarsson et al., Analysis of Antigens in Mycobacterium
Paratuberculosis, Acta. Vet. Scand. 1979, pp. 201-215, vol. 20.
Hamilton et al.. Mycobacterium paratuberculosis Monoassociated
Nude Mice as a Paratuberculosis Model, Vet. Pathol., 1991, pp.
146-155, No. 28.
Homuth et al., Identification and Characterization of a Novel

Extracellular Ferric Reductase from Mycobacterium
paratuberculosis, Inf & Immun., Feb. 1998, pp. 710-716, vol. 66, No.
2, Amer. Soc. Microb., USA.

Hseih et al., Two-dimensional electrophoretic analysis of
Mycobacterium avium and M. paratuberculosis iron-regulated pro
teins, Proc. Fifth Intl. Paratuberculosis, pp. 82-87.
Jacobs, Jr. et al., Genetic Systems for Mycobacteria, Meth. Enzy.
1991, pp. 537-555, vol. 204, Academic Press, USA.
Kwoh et al., Transcription-based amplification system and detection
of amplified human immunodeficiency virus type 1 with a bead
based sandwich hybridization format, Pro. Natl. Acad. Sci., Feb.
1989, pp. 1173-1177, vol. 86, Biochem., USA.
Landegren et al., A Ligase-Mediated Gene Detection Technique,
Science, Aug. 1988, pp. 1077-1080, vol. 241.
Martin et al., Transposition of an antibiotic resistance element in
mycobacteria, Nature, Jun. 1990, pp. 739-743, vol. 345.
McAdam et al., In Vivo Growth Characteristics of Leucine and

Methionine Auxotrophic Mutants of Mycobacterium bovis BCG
Generated by Transposon Mutagenesis, Inf and Immun., Mar. 1995,
pp. 1004-1012, vol. 63, No. 3, Amer. Soc. Microb., USA.
Mutharia et al., Analysis of Culture Filtrate and Cell Wal-Associated
Antigens of Mycobacterium Paratuberculosis with Monoclonal
Antibodies, Inf and Immun., Feb. 1997, pp. 387-394, vol. 65, No. 2,
Amer. Soc. Microb., USA.

Pelicic et al., Efficient allelic exchange and transposon mutagenesis
in Mycobacerium tuberculosis, Proc. Natl. acad. Sci., Sep. 1997, pp.
10955-10960, vol. 94.

Pelicic et al., Genetic advances for studying Mycobacterium Tuber
culosis pathogenicity, Mol. Microb., 1998, pp. 413-420, vol. 28, No.
3.

Shapiro-Hurley et al., Deoxyribonucleic Acid Relatedness of
Mycobacterium paratuberculosis to Other members of the Family
Mycobacteriaceae, Intl. J. Syst. Bacteriol. Apr. 1988, pp. 143-146.
vol. 38, No. 2, Intl. Union Microb. Soc.

St-Jean et al., Treatment of Mycobacterium paratuberculosis Infec
tion in Ruminants, Vet. Clin. N. Am. Food Anim. Prac., Nov. 1991, pp.
793-805, vol. 7, No. 3.

St-Jean, Treatment Of Clinical Paratuberculosis In Cattle, Vet. Clin.

N. Am. Food Anim. Prod, Jul. 1996, pp. 417-430, vol. 12, No. 2.
Stabel. An improved method for cultivation of Mycobacterium
paratuberculosis from bovine fecal samples and comparison to three
other methods, J. Vet. Diagn. Invest., 1997, pp. 375-380, vol. 9.
Stevenson. The Contribution of Molecular Biology to
Mycobacterium avium Subspecies paratuberculosis Research, Vet.
Jour:, 1997, pp. 269-286, vol. 153.
Sugden et al., Chromatographic Purification and Characterization of
Antigens A and D from Mycobacterium paratuberculosis and Their
Use in Enzyme-Linked Immunosorbent Assays for Diagnosis of
Paratuberculosis in Sheep, Jour: Clin. Microb. Aug. 1991, pp. 1659
1664, vol. 29, No. 8, Amer. Soc. Microb., USA.

Thorel et al., Numerical Taxonomy of Mycobactin-Dependent
Mycobacteria. Amended Description of Mycobacterium avium, and
Description of Mycobacterium avium subsp. avium Subsp. nov.,
Mycobacterium avium subsp. paratuberculosis Subsp. nov., and
Mycobacterium avium subsp. Silvaticum Subsp. nov. Int. J. System.
Bacteriol. Jul. 1990, pp. 254-260, vol. 40, No. 3, Inter. Union
Microb. Soc.

Van Schaik et al., Cost-benefit analysis of vaccination against
paratuberculosis in dairy cattle, Vet. Rec. Dec. 1996, pp. 624-627.
vol. 139.

Whipple et al., Development of the beige mouse as an animal model
for M. paratuberculosis infection, Proc. 3rd Intl. Colloq.
Paratuberculosis, pp. 551-552.
White et al., Comparison of cellular and extracellular proteins
expressed by various isolates of Mycobacterium paratuberculosis
and other mycobacterial species, Am. J. Vet. Res., Oct. 1994, pp.
1399-1405, vol. 55, No. 10.

Williams et al., Development of a Firefly Luciferase-Based Assay for
Determining Antimicrobial Susceptibility of Mycobacterium avium
subsp. paratuberculosis, J. Clin. Microb, Feb. 1999, pp. 304-309,
vol. 37, No. 2, Amer. Soc. Microb., USA.
Wu et al., The Ligation Amplification Reaction (LAR)-Amplification
of Specific DNA Sequences. Using Sequential Rounds of Template
Dependent Ligation, Genomics, 1989, pp. 560-569, vol. 4.
Coulter, S.N. et al., “Staphylococcus aureus Genetic Loci Impacting
Growth and Survival in Multiple Infection Environments'. Molecu
lar Microbiology, Oct. 1998, pp. 393-404, vol. 30, No. 2.
Darwin, A.J. et al., “Identification of Yersinia enterocolitica Genes

Affecting Survival in an Animal Host Using Signature-tagged
Transposon Mutagenesis'. Molecular Microbiology, Apr. 1999, pp.

51-62, vol. 32, No. 1.
Hensel, M. et al., “Simultaneous Identification of bacterial Virulence

Genes by Negative Selection”, Science, Jul. 1995, pp. 400-403, vol.
269.

Perry, R.D., "Signature tagged Mutagenesis and the Hunt for Viru
lence Factors'. Trends in Microbiology, Oct. 1999, pp. 385-388, vol.
7, No. 10.

Ramaswamy, S. et al., “Molecular genetic Basis of Antimicrobial
Agent Resistance in Mycobacterium Tuberculosis: 1998 Update'.
Tubercle and Lung Disease: The Official Journal of the International
Union Against Tuberculosis and Lung Disease, 1998, pp. 3-29, vol.
79, No. 1, Scotland.

Tang, C. et al., “Pathogen Virulence Genes—Implications for Vac
cines and Drug Therapy'. British Medical Bulletin, 1999, pp. 387
400, vol. 55, No. 2, England.
International Search Report, PCT/US01/00980.
Amsterdam, D., Susceptibility Testing of Antimicrobials in Liquid
Media, in Antibiotics in Laboratory Medicine, 4th ed., 1996, pp.
52-111, Williams and Wilkins, Baltimore, MD (Lorian, V., ed.).
Eisenstadt, et al., Gene Mutation, in Methods for General and

Molecular Bacteriology, 1994, pp. 297-316, ASM Press, Washington
D.C. (Gerhardt, et al., eds.).
Rest, R.F. and Speert, D.P Measurement of Nonosponic Phagocytic
Killing by Human and Mouse Phagocytes, in Bacterial Pathogenesis,
1997, pp. 475-492, Academic Press, San Diego, CA (Clark and
Bavoli, eds.).

U.S. Patent

So
SS

SS

Jun. 22, 2010

y

$is

o

3$

ha

&$

Sheet 1 of 2

nSt

8

US 7,740,867 B2

pay

&& yis

Ss

&

S
9,416
6,557

- 4.36
-

-- 2,322

------ - 227

FIG. 2

Beth-R
-a-

Beth-F
Tn5367

...TGTTAACG ggctottcgca..................................... tgcgaagagcc TGTTAACG.
GPM2O7

7 R RT GP W G | SAVA A L H G W S C. S GOP
- R T P G -- A
A L GW T G + P

XerC (M. leprae) 181 QRTA PFG VPA ADA LRGW DDGRP

75

203

U.S. Patent

Jun. 22, 2010

Sheet 2 of 2

US 7,740,867 B2

FIG. 3B

FIG. 3A
1.0X 109
10x108
1.OX107

10x1081.OX10
1.OX106
p1.0X 10

1.OX10

51.0 x 105

Cld

1.OX10
10x108 - BAYY3118
.UX U

-

O

-

1

-

- -

.10x108 - BAYY3118
10x10

2

OX

- O

TIME (DAYS)

1

2

-

3

4.

TIME (DAYS)

1.0X 109
8
1.0X 10-

OX

10x10
P

10x108

,

5

CD 10 X 10-

D-CYCLOSERINE

2OX

10x10'10x108 L D-CYCLOSERINE
1.0X 102 - - - O
1
2
3
4

TIME (DAYS)

TIME (DAYS)

US 7,740,867 B2
1.
METHOD FOR IDENTIFICATION OF
VIRULENCE DETERMINANTS
CROSS-REFERENCE TO RELATED
APPLICATIONS

This application is a divisional of U.S. patent application
Ser. No. 09/759,287, filed Jan. 11, 2001, which claims the

benefit of provisional application 60/175,433 filed Jan. 11,
2000, the disclosures of which are hereby incorporated by
reference in their entirety for all purposes.

10

Clin. N. Am. Food Anim. Pract. 7:793-804, 1991; St.-Jean,

Vet. Clin. N. Am. Food Anim. Pract., 12:417-430, 1996), and

STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH ORDEVELOPMENT

no antibiotic treatment is recommended for clinical cases of
15

This invention was made with government funds under
98-35204-6761 and 99-35204-7789 awarded by United
States Department of Agriculture/CSREES. The U.S. Gov
ernment has rights in this invention.
BACKGROUND OF THE INVENTION

Paratuberculosis (Johne's disease) is an incurable, fatal
disease of domestic and wild ruminants. Mycobacterium
paratuberculosis (M. paratuberculosis) is the etiologic agent
of this disease. Mycobacterium avium (M. avium) and M.
paratuberculosis are slow-growing faculative intracellular
mycobacteria able to grow in mononuclear phagocytes.
DNA-DNA hybridization studies have shown that these
micro-organisms belong to a single genomic species (Hurley
et al., Intl. J. Syst. Bacteriol., 38: 143-146, 1988), and it has
been proposed to reclassify M. paratuberculosis as a subspe
cies of M. avium (Thorel et al., Intl. J. Syst. Bacteriol. 40:254
260, 1990). Furthermore, all M. paratuberculosis strains are
characterized by the presence of the insertion sequence IS900
(Green et al., Nucleic Acids Res., 17:9063-9073, 1989),
which is absent from most M. avium strains. Phenotypic
differences between M. avium and M. paratuberculosis. Such
as mycobactin requirement, ability to grow on egg medium,
growth stimulation by pyruvate, and tolerance to cycloserine
correlate with variations in pathogenicity and host range
(Thorel et al., Intl. J. Syst. Bacteriol. 40:254-260, 1990).
Johne's disease is manifested by chronic diarrhea and
weight loss. After months of diarrhea and wasting, the
affected animals either die or are culled. In the United States,
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the prevalence of M. paratuberculosis infection in dairy and
beef cattle herds has reached 34% in certain areas (Collins et
al., J. Am. Vet. Med. Assn. 187:323-329, 1992; Collins et al.,

J. Am. Vet. Med. Assn. 204:636-641, 1994) and results in
millions of dollars in lost revenues annually. Furthermore, M.
paratuberculosis has been tentatively linked to Crohn's dis
ease, a chronic granulomatous ileitis in humans. Evidence
Supporting the possibility that M. paratuberculosis is the
etiologic agent of Crohn's disease includes culture of M.
paratuberculosis is from intestinal tissue, and amplification
by PCR of the subspecies-specific IS900 sequence of M.
paratuberculosis from biopsy specimens.
Natural infection in cattle is usually acquired in the first
months of life. The age of onset of clinical Johne's disease
varies, being most frequent during or after the second lacta
tion in dairy cattle. The prolonged incubation time and the
difficulty in diagnosing Subclinical cases facilitate the insidi
ous spread of the infection within a herd. Bacteriologic cul
ture is the most definitive diagnostic method, but requires
substantial time and labor (Stabel, J. Vet. Diag. Invest., 9:375
380, 1997), and it is unable to detect infected animals that do
not shed acid-fast bacilli. Progress has been made by com

2
bining fecal culture, PCR detection (IS900), and tests for
humoral (ELISA) or cellular immunity (IFN-Y test) (Collins,
Proceedings of the Fifth Intl. Colloq. Paratuberculosis, Chio
dini et al., eds. Intl. Assn. for Paratuberculosis, 1997, pp.
232-241.). More recently, a gene unique to M. paratubercu
losis (hspX) was identified and has promise as a new diag
nostic tool (Ellingson et al., Mol. Cell Probes 12:133-142,
1998).
Currently, treatment of paratuberculosis in cattle is limited
to the extra label use of therapeutic agents (St.-Jean et al., Vet.

50
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Crohn's disease. Even with a prolonged drug regimen paratu
berculosis in cattle is invariably fatal.
Little is known about M. paratuberculosis immunogens
and virulence determinants (Cocito et al., Clin. Microbiol.
Rev. 7:328-345, 1994). Lipoarabinoman (Sugden et al., J.
Clin. Microbiol., 29:1659-1664, 1991), glycopeptidolipid 1
(Camphausen et al., Proc. Natl. Acad. Sci. USA, 82:3068
3072, 1985), and 35 kDa (p35) antigen (El Zaatari et al., J.
Clin. Microbiol., 35:1794-1799, 1997) are three major immu
nogens. Antigen p35 was recognized by Sera from all clini
cally diseased cattle and by fifteen out of twenty cattle with
Subclinical diseases. This antigen, however, is not specific for
paratuberculosis, since it is widely present in other strains of
the M. avium complex. Several protein antigens have been
identified by two-dimensional immunoelectrophoresis with
hyperimmune Sera, but only a Subset of these antigens are
recognized by Sera from animals with paratuberculosis (Gun
narsson and Fedstand, Acta Vet. Scand. 20:200-215, 1979).
Comparison of the two-dimensional gel electrophoretic pro
files of M. paratuberculosis and M. avium cells grown in
Middlebrook 7H9 medium followed by Western blot analy
sis, using antiserum from clinically infected cows, revealed a
42 kDa protein which may be specific for M. paratuberculosis
(White et al., Am. J. Vet. Res., 55:1399-1405, 1994). Using the
same methodology, AHPC gene products were identified that
may be antigenic (Hsieh et al., Proceed. Fifth Intl. Colloq.
Paratuberculosis, Chiodini et al., eds., 1997, pp. 82-87).
M. paratuberculosis antigens that have been cloned
include the heat shock proteins HSP65 and HSP70, the trans
posase form IS900, a putative serine protease, bacteriofer
ritin, the 34 kDa antigen bearing major B cell epitopes (re
viewed by Stevenson and Sharp, Vet. J. 153:269-286, 1997),
and more recently, the 35 kDa antigen (El Zaatari et al., J.
Clin. Microbiol. 35:1794-1799, 1997) and the fled protein
from IS900 (Doran et al., Microbiol. 143:547-552, 1997). In
addition, a novel extracellular ferric reductase enzyme activ
ity with a potential role in the evasion of intracellular defense
mechanisms has been identified (Homuth et al. Infect.
Immun., 66:710-716, 1998). Secreted proteins of M. paratu
berculosis have received attention as potential immune tar
gets early in infection. Some of these proteins are present as
glyconjugates and different epitopes in the glycosylated and
non-glycosylated moieties seem to be recognized in cattle
and sheep (Mutharia etal, Infect. Immun. 65:387-394, 1997).
Diagnosis and control of paratuberculosis presents a sig
nificant challenge. Although vaccination does reduce clinical
signs of Johne's disease, it does not prevent losses in milk
production (van Schaik et al., Vet. Rec., 139:624-627, 1996).
Improved vaccines and diagnostic tools are urgently needed.
Likewise faster, specific, and more accurate and sensitive
diagnostics need to be developed, especially to detect animals
in the early stages of the disease. These tools preferably
should also be able to discriminate between vaccinated and
infected animals.

US 7,740,867 B2
4
Another aspect provides a method for diagnosing infection
by Mycobacterium paratuberculosis comprising obtaining a
sample from an animal and determining the presence or
absence in the sample of a bacterial virulence determinant,
said determinant identified by the methods described above.

3
Identification of M. paratuberculosis virulence determi
nants is a critical step in developing Suitable methods of
diagnosis and control, and requires a systematic method by
which virulence determinants can be found. U.S. Pat. No.

5,783.386 to Jacobs et al. describes a method for identifying
virulence determinants of mycobacterial species involving
the preparation of a genomic DNA library and constructing
shuttle vectors containing inserts from the library con

BRIEF DESCRIPTION OF THE DRAWINGS

structed. These vectors are then used to transform a virulent

organisms to form recombinants. Virulence determinants are
identified by inoculating animals with the transformed
recombinant organisms to select virulent recombinants and
then identifying the DNA sequences that confer virulence.
Cavaignac, et al. (Arch. Microbial. 173:229-231, 2000) stud
ied virulence mechanisms in M. paratuberculosis by the
introduction of random mutants using transposon mutagen

10

15

medium.
25

BRIEF SUMMARY OF THE INVENTION

Among the several aspects of the invention is provided a
method for identifying virulence determinants of a bacteria
comprising introducing at least one mutation into the genome
of a bacteria; culturing the mutated bacteria in the presence of
an antimicrobial agent that kills growing but not non-growing
bacteria; selecting Surviving bacteria; testing the selected Sur
viving bacteria for virulence; selecting the non virulent bac
teria; sequencing genetic material from the selected non viru
lent bacteria; determining the site of mutation; and comparing
the sequence at the mutated site to the corresponding wild
type Sequence.

Another aspect provides a composition for immunizing an
animal against bacterial infection comprising a pharmaceuti
cally acceptable carrier, diluent or excipient; and at least one
non-virulent strain of bacteria produced by the process com
prising introducing at least one mutation into the genome of a
bacteria; culturing the mutated bacteria in the presence of an
antimicrobial agent that kills growing but not non-growing
bacteria; selecting Surviving bacteria; testing the selected Sur
viving bacteria for virulence; and selecting the non-virulent
strains.

Still another aspect provides a composition for immuniz
ing an animal against a bacteria comprising a pharmaceuti
cally acceptable carrier diluent or excipient; and at least one
bacterial virulence determinant, the determinant identified by
a process comprising; introducing at least one mutation into
the genome of a bacteria; culturing the mutated bacteria in the
presence of an antimicrobial agent that kills growing but not
non-growing bacteria; selecting Surviving bacteria; testing
the selected surviving bacteria for virulence; selecting the
non-virulent strains; sequencing genetic material from the

30

ABBREVIATIONS AND DEFINITIONS

cfu colony forming unit
pful plaque forming unit
MIC-minimal inhibitory concentration
Albumin dextrose complex’ means 2 g glucose, 5 g
bovine serum albumin fraction V and 0.85g NaCl in 100 mL
deionized water.
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As used herein “polynucleotide' and "oligonucleotide' are
used interchangeably and refer to a polymeric (2 or more
monomers) form of nucleotides of any length, either ribo
nucleotides or deoxyribonucleotides. Although nucleotides
are usually joined by phosphodiester linkages, the term also
includes polymeric nucleotides containing neutral amide
backbone linkages composed of aminoethyl glycine units.
This term refers only to the primary structure of the molecule.
Thus, this term includes double- and single-stranded DNA
and RNA. It also includes known types of modifications for
example, labels, methylation, "caps'. Substitution of one or
more of the naturally occurring nucleotides with an analog,
internucleotide modifications such as, for example, those
with uncharged linkages (e.g., methyl phosphonates, phos
photriesters, phosphoamidates, carbamates, etc.), those con
taining pendant moieties, such as, for example, proteins (in
cluding for e.g., nucleases, toxins, antibodies, signal
peptides, poly-L-lysine, etc.), those with intercalators (e.g.,
acridine, psoralen, etc.), those containing chelators (e.g., met
als, radioactive metals, boron, oxidative metals, etc.), those
containing alkylators, those with modified linkages (e.g.,
alpha anomeric nucleic acids, etc.), as well as unmodified
fowls of the polynucleotide. Polynucleotides include both
sense and antisense Strands.
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selected non-virulent bacteria to determine the site of the

mutation; and identifying the virulence determinant based on
the site of the mutation.

Yet another aspect provides a method for inducing an
immune response in an animal against a bacteria comprising
administering to an animal an immune response inducing
amount of any of the previously described compositions.

FIG. 2 shows the location of the BETH-R and BETH-F

primers in the Tn5367 on and partial results of sequencing.
Also shown is the alignment of nucleotide sequence obtained
from mutant GPM207 (SEQ ID NO: 5) using BETH-F and
the xerC gene (GenBank No. Z97369) (SEQID NO: 6).
FIG. 3 shows the effects of co-culture with either Bay y
3118 or D-cycloserine on growing and non-growing M.
paratuberculosis strain K-10 in complete Middlebrook 7H9

esis. Two thousand mutants were screened on the basis of

auxotrophy and altered cell wall. Pelicic et al. (U.S. Pat. No.
6,096,549) disclose a method for inserting a transposon into a
mycobacterium strain using a vector containing the sacB
gene. Use of this vector to identify virulence determinants is
also disclosed. The present disclosure teaches an alternative
method utilizing transposon mediated mutation and positive
selection of mutants by antimicrobial agents that kill growing
mycobacteria.

These and other features, aspects, and advantages of the
present invention will become better understood with regard
to the following description, appended claims and accompa
nying figures where:
FIG. 1 shows Southern blot analysis of M. paratuberculo
sis K-10 true transposon mutants.
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As used herein “polypeptide”, “protein’ and "peptide' are
used interchangeably and refer to a polymer of two or more
amino acids. Included within the definition are polypeptides
containing one or more analogs of an amino acid, including,
for example, unnatural amino acids, polypeptides with Sub
stituted linkages, as well as modifications known in the art,
both naturally occurring and non-naturally occurring.
As used herein, the term “animal' includes human beings.
As used herein, the term “patient' includes humans and
animals.
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DETAILED DESCRIPTION OF PREFERRED
EMBODIMENT

The following detailed description is provided to aid those
skilled in the art in practicing the present invention. Even So,
this detailed description should not be construed to unduly
limit the present invention as modifications and variations in
the embodiments discussed herein can be made by those of
ordinary skill in the art without departing from the spirit or
Scope of the present inventive discovery.
All publications, patents, patent applications, databases
and other references cited in this application are herein incor
porated by reference in their entirety as if each individual
publication, patent, patent application, database or other ref
erence were specifically and individually indicated to be
incorporated by reference.
The present invention relates to the method for identifica
tion of virulence determinants in bacteria particularly in
members of the genus Mycobacterium. The genus Mycobac
terium includes the species M. phlei, M. Smegmatis, M. afri
canum, M. fortuitum, M. marinum, M. ulcerans, M. tubercu
losis, M. bovis, M. microti, M. avium, M. paratuberculosis, M.
leprae, M. lepraemurium, M. intracellulare, M. Scrofiulla
ceum, M. xenopi, M. genavense, M. kansasii, M. Simiae, M.
Szulgai, M. haemophylum, M. asiaticum, M. amlimoense, and
M. Shimoidei. In one embodiment, the mycobacteria are slow
growing mycobacteria. Any virulent strain of a species of
mycobacterium that is slow growing and capable of being
maintained in vitro can be used in the practice of the present
invention. Examples of slow growing mycobacteria include
M. tuberculosis, M. bovis, M. africanum, M. marinum, M.
avium, and M. paratuberculosis. In one embodiment, strains
of M. paratuberculosis are used and in particular the virulent
strain K-10 of M. paratuberculosis.
Once a particular strain or strains has been chosen, muta
tions are introduced into the genome of the selected bacteria.
Numerous means for inserting mutations into the genome of
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chromosome of a bacteria to be mutated. As used herein, the
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directed to a particular gene or sequence of interest, or the
location of the mutations can be random. Ifrandom mutation

al., J Bacterol. 178:273-279, 1996; McFadden. Molec. Micro
biol., 21:205-211, 1996: Pelicic et al., Proc. Natl. Acad. Sci.

USA, 94:10955-10960, 1997).

Acad. Sci. USA, 94:10961-10966, 1997). In one preferred
embodiment, transposon mutagenesis is accomplished by use
of the transposable element Tn5367, a single-unit transposon
which carries a kanamycin-resistance marker and the M.
Smegmatis insertion sequence IS 1096 (Cirillo et al., J. Bacte
rol. 173:7772-7780, 1991; McAdam et al., Infect. Immunol.,
1004-1012, 1995).
Introduction of vectors useful in the practice of the present
invention can be accomplished by any suitable method known
in the art. Various methods are known for the introduction of

biol., 28:413-420, 1998. Mutations introduced can be site

is used, it is preferred that the mutations be approximately
evenly distributed throughout the genome. Two particularly
useful forms of mutagenesis are allelic exchange mutagenesis
and transposon mutagenesis although other forms of
mutagenesis Such as chemical and enzymatic (e.g. restriction
enzyme mediated integration) mutagenesis can be used.
In allelic exchange mutagenesis, the gene or sequence of
interest is disrupted using homologous recombination Such
that the functional allele is replaced with an inactivated copy.
Following introduction of the inactivated copy, the virulence
of the transformed bacteria can be compared to the parental
strain. The efficiency of allelic exchange mutation is
improved through the use of counter selection strategies
which eliminate transformants retaining the delivery vector.
Successful allelic exchange mutations have been achieved in
mycobacteria (U.S. Pat. No. 6,096,549; Balasubramanian et

term “transposon’ is a general term and encompasses both
non-mutated and mutated transposons. Thus, the term
includes transposons in which a portion of the nucleotide
sequence has been deleted and/or replaced, and/or wherein
the transposon contains additional DNA sequences. Transpo
son mutagenesis has been Successfully used in mycobacteria
(Martin et al., Nature, 345:739-743, 1990; Guilhot et al., J
Bacteriol. 176:535-539, 1994; Pelicic et al., Proc. Natl. Acad.
Sci USA, 94:10955-10960, 1997: Bardarov et al., Proc. Natl.

bacteria are known in the art and can be found in standard

references such as Sambrook et al. Molecular Cloning, 2nd
ed., Cold Spring Harbor Press, 1989 and Ausubel et al., Short
Protocols in Molecular Biology, 3rd ed., Wiley, 1995. A dis
cussion of methods of mutagenesis directed particularly to
mycobacteria can be found in Jacobs et al., Methods in Enzy
mology, 204:537-555, 1991 and Pelicic et al., Molec. Micro
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In one embodiment, the introduction of mutations is by
transposon mutagenesis. Transposon mutagenesis occurs by
the insertion of a mobile element called a transposon into the
gene or sequence of interest, thus disrupting its function. An
advantage of transposon mutagenesis is that no previous
assumptions need to be made regarding the identity of the
gene or sequence to be disrupted. In general, a transposon
contains an inverted repeat sequence at the 5' and 3' ends and
a gene or genes encoding transposase enzyme(s) between the
inverted repeats. In transposon mutagenesis, the transposon is
removed from a vector and inserted or transposed into the
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DNA into bacterial cells and include, for example, calcium
phosphate transfection, DEAE-dextran mediated transfec
tion, Polybrene, protoplast fusion, liposomes, phage infec
tion, conjugation, and electroporation. Commonly, introduc
tion of vectors for allelic exchange or transposon mutagenesis
in mycobacteria is by either electroporation or phage infec
tion. In one preferred embodiment, introduction of the DNA
is by phage infection and in particular by the use of the TM4
thermosensitive transposon delivery shuttle plasmid phaE94
(Bardarov et al. Proc. Natl. Acad. Sci. USA,94:10961-10966,
1997).
In general, a shuttle plasmid comprises a bacteriophage
DNA into which a plasmid sequence has been inserted into a
nonessential region. In one embodiment, the bacteriophage is
from a mycobacteriophage and the plasmid sequence is a
cosmid sequence, preferably an E. coli cosmid sequence.
Shuttle plasmids can, therefore, replicate in bacteria as a
plasmid/cosmid or as a phage. The inserted plasmid/cosmid
DNA is preferably flanked by restriction sites not found in the
bacteriophage DNA, so that the inserted DNA can be easily
excised. In one embodiment, a cosmid containing a transpo
son is obtained and inserted into the bacteriophage backbone
using standard methods of cosmid cloning (Sambrook et al.,
Molecular Cloning, 2nd ed., Cold Spring Harbor Press,
1989).
The sequence containing the transposon can, and usually
does, also contain a selection marker sequence. Typically, this
sequence encodes a protein necessary for the Survival or
growth of the host cell transformed with the shuttle plasmid.
Examples of suitable markers for prokaryotic cells include
tetracycline, kanamycin, and amplicillin resistance.
In one embodiment, the shuttle plasmid is a temperature
sensitive plasmid. Temperature sensitive shuttle plasmids are
those which replicate and form plaques at a permissive tem
perature, but do not undergo a lytic cycle and so do not form
plaques at a non-permissive temperature.

US 7,740,867 B2
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Once the temperature sensitive shuttle plasmid has been
produced it can be introduced into a bacterial host which will
allow growth of the shuttle plasmid as alytic bacteriophage at
a permissive temperature. Introduction of the shuttle plasmid
into the host cell can be by any method suitable for the
introduction of DNA into a bacterial host including those
discussed above. Introduction of the shuttle plasmid and cul
ture at a permissive temperature results in the production of
large numbers of bacteriophage particles. The bacteriophages
are isolated using standard techniques and then used to infect
Susceptible bacteria at a non permissive temperature. At the
non-permissive temperature, rather than causing lysis of the
infected bacteria, the shuttle plasmid gives rise to bacterial

5

10

liams et al., J. Clin. Microbiol. 37:304-309, 1999. In one

embodiment, mycobacteria are grown in Middlebrook 7H9

transductants which can then be selected on the basis of a

selection marker, if present.
In one preferred embodiment, introduction of the DNA is
by the use of the TM4 thermosensitive transposon delivery
shuttle plasmid phaE94 (Bardarov et al. Proc. Natl. Acad.
Sci. USA, 94:10961-10966, 1997). This shuttle plasmid con
tains the transposon Tn5367 which is a derivative of the
insertion sequence IS1096 from M. Smegmatis and carries the
aph gene conferring kanamycin resistance. In this embodi
ment, phaE94 is propagated in M. Smegmatis at a permissive
temperature and the resulting mycobacteriophage used to
infect Susceptible mycobacteria at a non-permissive tempera
ture. Mycobacteria undergoing transformation are then
selected by kanamycin resistance.

15
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Once one or more mutations have been introduced into the

genome, a selection method is employed in order to select
those bacteria which the mutation has disrupted a gene or
nucleic acid sequence potentially involved in virulence. Vari
ous methods can be employed to determine virulence. For
example, Suitable host animals can be inoculated with the
mutated bacteria and monitored for development of disease
symptoms and/or replication of the organisms injected. Alter
natively, selection can be based on the use of a chemical, and
in particular, an antimicrobial, the effect of which is associ
ated with a trait related to virulence. Since bacterial growth is
a necessary part of virulence, in one embodiment the selec
tion is based on the ability of an antimicrobial to kill growing
mycobacteria while having a reduced or no effect on non
growing bacteria. Thus, antimicrobials that interfere with
processes involved in bacterial growth and in particular DNA
replication are preferred. Although not necessary to practice
the present invention, it is preferred that the antimicrobial
agent used be able to enter eukaryotic cells, thus allowing
screening of transformed bacteria in intracellular culture sys
tems, e.g. macrophage culture. In one embodiment, the anti
microbial is a quinolone. In another embodiment, the antimi
crobial is a fluoroquinolone. In yet another embodiment, the
antimicrobial is Bayy 31 18. Bayy 3118 has been reported to
kill growing but not non-growing Mycobacterium avium
within human macrophages (Bermudez et al., FEMS Micro
bial. Lett. 1787:19-26, 1999). In still another embodiment,
the antimicrobial is D-cycloserine (Cáceres et al., J. Bacte
riol. 179:5046-5055, 1997).
The exact amount of the antimicrobial used will vary with
the particular Substance and organism in question. In general,
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broth. As is known in the art and described in the references

cited above, Middlebrook 7H9 broth is supplemented
depending on the particular species of mycobacteria cultured.
Alternatively, an intracellular culture system such as a mac
rophage or amoeba (Cirillo et al., Infect. Immunol. 65:3759
3767, 1997) culture system can be used. Mycobacteria natu
rally infect macrophages as part of the disease process. Thus,
mycobacteria can be cultured in macrophages. In this system,
mycobacteria, preferably in a single cell Suspension, are
added to a culture of macrophages from a suitable species.
The macrophages used can be recently collected from blood
using known, standard methods or can be from a macrophage
cell line. The mycobacteria are allowed to infect the macroph
ages. The infected macrophages are then maintained under
suitable culture conditions so that the mycobacteria survive
and grow within the macrophages.
The antimicrobial selection agent is added to the culture
system at a concentration that exceeds the MIC and the cul
ture continued for a period of time sufficient to kill the mul
tiplying bacteria. It will be apparent to those skilled in the art
that the exact amount of time required will vary with such
well known factors as the amount and type of selection agent
used, the culture system, and the species of mycobacteria. In
general, the selection conditions can be optimized by cultur
ing bacteria for various times and at various concentrations of

40

antimicrobials to determine the combination of times and

45

concentrations which effectively kill growing, but not non
growing bacteria. Such optimization can readily be achieved
by the skilled technician without undue experimentation.
After the selection period, the surviving bacteria are col
lected, individual bacteria isolated, by for example clonal
streaking, and the clones expanded using standard culture
methods. If desired following expansion, the selected bacteria
can be further characterized by genetic, biochemical, and
animal testing.
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the concentration of the antimicrobial should exceed the

approximate minimal inhibitory concentration (MIC) for the
particular organism being studied. Determination of MIC is
routine in the art and can be accomplished by the skilled
technician without undue experimentation. In one embodi
ment, in which M. paratuberculosis strain K-10 and Bay y
31 18 are used, the MIC is approximately 0.015 lug/mL. In
another embodiment, the concentration of Bay y 3118 is 5x
the MIC. In still another embodiment in which M. paratuber

8
culosis strain K-10 and D-cycloserine are used the MIC is
approximately 25 ug/mL. In yet another embodiment, the
concentration of D-cycloserine is 5x the MIC.
In general, Screening is accomplished by culturing the
mutated bacteria in the presence of the antimicrobial agent.
As will be apparent to those skilled in the art, the exact culture
conditions will vary with the organism being studied. When
M. paratuberculosis is used, either broth or macrophage cul
ture can be used. Methods for the culture of mycobacteria are
well known in the art and can be found, for example, in Jacobs
et al., Methods in Enzymology, 204:537-555, 1991: Foley
Thomas et al. Microbiology 141:1173-1181, 1995; and Wil
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Characterization can include determination of whether the

transposon has been incorporated into the genome. This can
be accomplished using well known techniques such as South
ern blotting, dot or slot blots, and in situ hybridization to
bacterial chromosomes, using a polynucleotide probe com
plimentary to the transposon used. Information regarding the
location of the transposition and the gene or sequence dis
rupted can be obtained by sequencing. In general, this can be
accomplished by obtaining purified genomic DNA from
transfected bacteria and cutting the DNA with restriction
enzymes that do not cut within the transposon. The restriction
fragments obtained can be cloned into a cloning vector using
standard techniques and amplified for sequencing. Any
known method of sequencing can be used. In one embodi
ment, sequencing is accomplished by cycle sequencing out
ward from the transposon. Once the sequence information has
been obtained, the nucleic acid sequences or deduced amino
acid sequences can be compared to sequences in publicly

US 7,740,867 B2
available databases such as those maintained by the National
Center for Biotechnology Information at http://www.ncbi.nlm.nih.gov/, the European Bioinformatics Institute at http://
www.ebi.ac.uk/, The Institute for Genomic Researchat http://
www.tigr.org, The Sanger Centreat http://www.sanger.ac.uk/
Projects/. The Computational Biology Center of the
University of Minnesota Microbial Genome Project at http://
cbc.umn.edu/, and the Institute Pasteur at http://genolist.pas
teur.fr/. Based on sequence homology, the identity of the gene
or sequence disrupted by the insertion can be determined and

10

thus the virulence determinant identified.

Alternatively or additionally information can be obtained
by biochemical studies, especially by auxotrophic analysis.
Auxotrophic mutants are mutants that require a nutrient or
Substance not required by the parent organism from which the
mutant was derived. Determination of auxotrophic mutants
can be made by comparing growth on complete and incom
plete growth medium. For those mutants showing no or
reduced growth on incomplete medium, the missing nutrients
can be individually added back until growth comparable to
that seen with complete medium is obtained. Methods for
selecting auxotrophic mutants are well known in the art and
can be accomplished by the skilled technician without undue
experimentation.
Whether the selected mutants lack virulence can be tested

15
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by inoculating Susceptible animals with the selected organ
ism and determining if the organism results in clinical Symp
toms or if the organism multiples and spreads beyond the site
of inoculation. The animal inoculated can be the natural host

for the organism or it can be a animal model. In one embodi
ment, the mouse model and in particular the beige mouse
(Whipple et al. Proc. 3rd Intl. Colloq Paratuberculosis, Intl.
Assn. Paratuberculosis, pp. 551-552) is used for virulence
testing. In general, the animal is inoculated with a quantity of
the organism Sufficient to result in infection. Inoculation can
be oral, parenteral or any other suitable method. The exact
amount of the organism inoculated will vary with well known
factors such as the species, size and age-of the animal. Deter
mination of the proper quantity of organism to be adminis
tered can be determined by one of ordinary skill in the art
without undue experimentation. At various times after inocu
lation, the animals are sacrificed and various organs examined
for the presence of the organism. If the organism is not
detected, it can be assumed that the gene or sequence dis
rupted is a virulence determinant.
Confirmation that the sequence identified is a virulence
determinant can be obtained by a complementation study. In
a complementation study, the wild type sequence is reintro
duced into the mutated organism, for example by introduction
of an expression vector, and the effect on virulence deter
mined. If the disrupted sequence is associated with virulence,
replacement of the sequence should restore virulence. Ingen
eral, the disrupted gene or sequence is inserted into a suitable
expression vector using standard techniques in molecular
biology found in standard references and described herein.
The expression vector is then introduced into the mutant
organism and the virulence of the complemented organism is
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includes subcutaneous, intravenous, intramuscular, or
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tested as described above.

The method of the present invention can be used to create
strains of mycobacteria which are non-virulent or have

60

reduced virulence. As used herein the term attenuated refers

to mutated Strains whose virulence is reduced as compared to
the same organism in its non-mutated form. Such attenuated
mycobacteria can be used in compositions for the treatment
and/or prophylaxis of diseases caused by or associated with
the organism. This includes compositions designed to stimu
late an immune response against a organism, for example, a

10
vaccine. Attenuated strains produced by the method of the
present invention are thought to be particularly useful
because they make it possible to differentiate between indi
viduals who test positive for the presence of mycobacteria
due to vaccination or natural infection based on the presence
of the introduced transposon.
Likewise, polypeptides encoded by sequences identified
by the method of the present invention as being involved in
virulence can be used to stimulate an immune response in an
animal. In this embodiment, the sequence identified as
described herein is placed into an expression vector. If
desired, the polypeptide sequence identified can be fused or
assembled with additional amino acids to form a fusion pro
tein. Such fusion proteins can be used to increase the solubil
ity or antigenicity of the virulence polypeptide. Methods for
the production of fusion proteins are well known in the art and
can be found in standard molecular biology references. The
expression vector is, in turned, introduced into a suitable
prokaryotic or eukaryotic host cell and the encoded polypep
tide expressed. The resulting polypeptide is then purified
using standard biochemical techniques from lysates of the
host cells or from culture medium containing the host cells.
The compositions can be administered to any animal which
can become infected with a species of mycobacteria. In one
embodiment, the animal is a ruminant animal, more prefer
ably a Bovidae and more preferably still a member of the
genus Bos. When the composition comprises whole myco
bacteria, the bacteria can be live or they can be killed by any
Suitable means such as heating, chemical treatment, or dis
ruption of the bacterial cell. Bacteria can be in a preserved
state Such as in a lyophilized form which may or may not be
reconstituted prior to administration. The compositions can
comprise attenuated bacteria alone, virulence polypeptides
alone, or a combination of attenuated bacteria and virulence
polypeptides.
The compositions of the present invention can be admin
istered by a variety of routes and methods. Suitable routes and
methods of administration include orally, parenterally, by
inhalation spray, rectally intradermally, transdermally, or
topically in dosage unit formulations containing conventional
nontoxic pharmaceutically acceptable carriers, adjuvants,
and vehicles as desired. The term parenteral as used herein

65

intrasternal injection, or infusion techniques. In one embodi
ment, the complexes are administered by injection. In another
embodiment, the compositions are administered orally. In yet
another embodiment, the compositions are administered by
inhalation. Methods for the formulation of drugs is well
known in the art and is discussed in, for example, Hoover,
John E., Remington's Pharmaceutical Sciences, Mack Pub
lishing Co., Easton, Pa. (1975), and Liberman, H. A. and
Lachman, L. Eds. Pharmaceutical Dosage Forms, Marcel
Decker, New York, N.Y. (1980).
Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions, can be formulated
according to the known art using Suitable dispersing or wet
ting agents and Suspending agents. The sterile injectable
preparation may also be a sterile injectable solution or Sus
pension in a nontoxic parenterally acceptable diluent or Sol
vent, for example, as a solution in 1,3-butanediol. Among the
acceptable vehicles and solvents that may be employed are
water, Ringer's solution, and isotonic sodium chloride solu
tion. In addition, Sterile, fixed oils are conventionally
employed as a solvent or Suspending medium. For this pur
pose, any bland fixed oil may be employed, including Syn
thetic mono- or diglycerides. In addition, fatty acids Such as
oleic acid are useful in the preparation of injectables. Dim
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ethyl acetamide, Surfactants including ionic and non-ionic
detergents, and polyethylene glycols can be used. Mixtures of
Solvents and wetting agents such as those discussed above are

12
Such as, interleukin-1, interleukin-2, interleukin-4, interleu

kin-6, interleukin-12, interferon-C, interferon-Y, granulo
cyte-colony Stimulating factor.

also useful.

Suppositories for rectal administration of the compositions
discussed herein can be prepared by mixing the active agent
with a suitable non-irritating excipient such as cocoa butter,
synthetic mono-, di-, or triglycerides, fatty acids, or polyeth
ylene glycols which are solid at ordinary temperatures, but
liquid at the rectal temperature, and which will therefore melt
in the rectum and release the composition.
Solid dosage forms for oral administration may include
capsules, tablets, pills, powders, and granules. In Such solid
dosage forms, the compounds of this invention are ordinarily
combined with one or more adjuvants appropriate to the
indicated route of administration. If administered per os, the
compounds can be admixed with lactose, Sucrose, starch
powder, cellulose esters of alkanoic acids, cellulose alkyl
esters, talc, Stearic acid, magnesium Stearate, magnesium
oxide, Sodium and calcium salts of phosphoric and Sulfuric
acids, gelatin, acaciagum, sodium alginate, polyvinylpyrroli
done, and/or polyvinyl alcohol, and then tableted or encap
Sulated for convenient administration. Such capsules or tab

In another embodiment, the virulence determinants iden
5

10

15

cells in culture medium.

lets can contain a controlled-release formulation as can be

provided in a dispersion of active compound in hydroxypro
pylmethyl cellulose. In the case of capsules, tablets, and pills,
the dosage forms can also comprise buffering agents such as
Sodium citrate, or magnesium or calcium carbonate orbicar
bonate. Tablets and pills can additionally be prepared with
enteric coatings.
For therapeutic purposes, formulations for parenteral
administration can be in the form of aqueous or non-aqueous
isotonic sterile injection Solutions or Suspensions. These solu
tions and Suspensions can be prepared from Sterile powders or
granules having one or more of the carriers or diluents men
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tioned for use in the formulations for oral administration. The

compounds can be dissolved in water, polyethylene glycol,
propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil,
sesame oil, benzyl alcohol, Sodium chloride, and/or various
buffers. Other adjuvants and modes of administration are well
and widely known in the pharmaceutical art.
Liquid dosage forms for oral administration can include
pharmaceutically acceptable emulsions, Solutions, Suspen
sions, syrups, and elixirs containing inert diluents commonly
used in the art, such as water. Such compositions can also
comprise adjuvants, such as wetting agents, emulsifying and
Suspending agents, and Sweetening, flavoring, and perfuming
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agents.

The amount of attenuated organism and/or virulence deter
minants that can be combined with the carrier materials to

50

produce a single dosage form will vary depending upon the
patient or animal and the particular mode of administration.
Compositions of the present invention can be given as a single
administration or in multiple administrations over a period of
time. If desired, after the initial administration or series of

administrations, additional periodic administrations (e.g.
boosters) of the composition can be given.
The attenuated organisms and/or virulence determinants
can be administered in combination with a pharmaceutically
acceptable immune system stimulant or adjuvant. Examples
of Such immune system stimulants or adjuvants include, but
are not limited to, Alum (aluminum phosphate or aluminum
hydroxide), Freund's adjuvant, calcium phosphate, beryllium
hydroxide, dimethyl dioctadecyl ammonium bromide,
saponins, polyanions, e.g. poly A:U, Ouil A, inulin,
lipopolysaccharide endotoxins, liposomes, lysolecithins,
Zymosan, propionibacteria, mycobacteria, and cytokines,

tified by the method of the present invention are used for
diagnosis of mycobacterial infection. Biological samples can
be obtained from a subject suspected of suffering from a
mycobacterial infection. Biological samples include any
sample of tissue or fluid isolated from an individual.
Examples of biological samples, include, but are not limited
to plasma, serum, spinal fluid, lymph fluid, sections of skin,
respiratory, intestinal, and genitourinary tracts, tears, saliva,
mucus, milk, blood cells, tumors, tumor cells, and organs.
Biological samples also include samples obtained from in
vitro cell culture, for example, cells grown in culture, includ
ing putatively infected cells and recombinant cells, cell com
ponents, and conditioned media resulting from the culture of
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In one embodiment, diagnosis is made based on the pres
ence of polynucleotide sequences identified by the method of
the present invention. In this embodiment, a biological
sample which contains nucleic acids is obtained from an
individual. Polynucleotides whether in the form of DNA or
RNA are obtained from the sample using well established
techniques which are known to those in the art and can be
found instandard molecular biology references. Such as those
cited herein. In one embodiment, diagnosis is made based on
hybridization of specific polynucleotide probes to sequences
encoding virulence determinants identified by the present
invention. Probes should be of sufficient length to provide
specificity. In general, probes are at least 4 nucleotides in
length, more preferably at least 8 nucleotides in length, even
more preferably at least 12 nucleotides in length, and more
preferably still at least 20 nucleotides in length. Probes used
can be obtained from mycobacteria using standard methods,
for example, by the use of restriction enzyme digestion to
obtain Suitable nucleic acid fragments which are then inserted
into a cloning vector, which is in turn introduced into a Suit
able host cell. The host cells are then grown under conditions
allowing replication of the cloning vector, and the desired
sequences isolated and used as probes. Alternatively, probes
can be produced by chemical synthesis in automated systems
by any suitable method, for example, the phosphoramidite
method of Beaucage and Carruthers (Teta. Letts., 22:1859
1862, 198). When used for hybridization, it is desirable that
the probes be completely complementary to the sequence to
be detected, but probes which exhibit only partial comple
mentarity can be used. Hybridization probes can, and often
do, contain detection moieties. Such detection moieties
include, but are not limited to radioactive labels, such as

radionuclides, fluorophores or fluorochromes, peptides,
enzymes, vitamins and steroids.
In order to insure specificity hybridizations should be con
ducted under highly stringent conditions. As is recognized in
the art stringency is a combination of many factors such as
temperature and the composition of the hybridization and
wash solutions. Thus, many different conditions can result in
the same degree of stringency. In general, highly stringent
conditions are achieved by hybridization in a solution of
6xSSC or SSPE at a temperature 20-25°C. below the melting
temperature (T) for DNA-DNA hybrids and 10-15° C.
below the T for DNA-RNA hybrids followed by washing in
0.1 xSSC or SSPE at 42°C. Even higher stringency conditions
can be achieved by washing in 0.1xSSC or SSPE at 50-65° C.
In situations where the amount of nucleic acid which can be

obtained from the sample is small, it may be desirable to
amplify the sequences of interest by methods such as the
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polymerase chain reaction (PCR), the ligase chain reaction
(LCR) (see, Wu and Wallace, Genomics, 4:560-569, 1989;
Landegren et al., Science, 241:1077-1080, 1988), transcrip
tion amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA,
86: 1173-1177, 1989), self-sustained sequence replication
(Guatelli et al., Proc. Natl. Acad. Sci. USA, 87: 1874-1878,
1990), and nucleic acid based sequence amplification
(NASBA). In one preferred embodiment, amplification is by
PCR. Optimization of conditions for conducting PCR must
be determined for each reaction and can be accomplished
without undue experimentation by one of ordinary skill in the
art. In general, methods for conducting PCR can be found in

14
tion of B lymphocytes with oncogenic DNA, or transfection
of Epstein-Barr virus. Panels of hybridomas can then be
screened for the production of suitable monoclonal antibod
ies using standard techniques. Methods for the production of
monoclonal antibodies are well known in the art and can be

found for example in U.S. Pat. Nos. 4.341,761; 4,399,121:
4,427,783; 4,444,887; 4,466,917; 4,472,500; 4,491,632; and
4493,890.

10

U.S. Pat. Nos. 4,965,188, 4,800,159, 4,683.202, and 4,683,

195; Ausbel et al., eds. Short Protocols in Molecular Biology,

3" ed., Wiley, 1995; and Innis et al., eds. PCR Protocols,

15

Academic Press, 1990.

Diagnosis of infection by the presence of sequences iden
tified by the method of the present invention can be achieved
by visualization of PCR products of a characteristic size.
Individuals testing positive due to natural infection can be

EXAMPLES

Example 1

differentiated from individuals who have received attenuated

vaccine by the presence of the transposon which will result in
an increase in the size of the amplification product. Alterna
tively, the amplification products could be detected by hybrid
ization to specific probes as described above.
In another embodiment, diagnosis is made by detection of
polypeptides encoded by the sequences identified by the
method of the present invention. In one embodiment, Such
detection is by an immunological assay. Various immunologi
cal assays known in the art can be used, including but not
limited to competitive and non-competitive assay systems
using techniques such as radioimmunoassays, ELISA (en
Zyme linked immunosorbent assay), 'sandwich’ immunoas
says, immunoradiometric assays, gel diffusion precipitin
reactions, immunodiffusion assays, in vivo immunoassays
(using colloidal gold, enzyme or radioisotope labels, for
example), western blots, immunoprecipitation reactions,
agglutination assays (e.g., gel agglutination assays, hemag
glutination assays), complement fixation assays, immunof
luorescence assays, protein A assays, and immunoelectro
phoresis assays, etc. In one embodiment, antibody binding is
detected by detecting a label on the primary antibody. In
another embodiment, the primary antibody is detected by
detecting binding of a secondary antibody or reagent to the
primary antibody. In a further embodiment, the secondary
antibody is labeled.
Antibodies, either polyclonal or monoclonal, against
polypeptides identified by the method of the present invention
for use in immunological assays can be produced by known
methods. If polyclonal antibodies are desired, an animal is
immunized with a virulence polypeptide identified by the
method of the present invention. The composition used for
immunization can comprise the polypeptide alone or may
further comprise an adjuvant or other immune system stimu
lant. Further, the polypeptide can be conjugated to a carrier
molecule or be part of a fusion protein in order to increase
antigenicity. Following immunization, serum is collected
from the immunized animals and treated according to well
established methods. If desired, the antibody can be purified
using known techniques such as affinity chromatography.
Methods for the production of polyclonal antibodies are well
known in the art and can be found for example in Ausubel et
al., Short Protocols in Molecular Biology, 3rd ed. Wiley,

Bacterial Strains, Growth Conditions, and
Recombinant DNA
25

A virulent clinical isolate of M. paratuberculosis (strain
K-10) was used. M. paratuberculosis cultures were grown
standing at 37°C. in a complete growth medium comprising
Middlebrook 7H9 broth enriched with oleic acid albumin
30

35

40

dextrose complex, 0.4% casamino acids containing vitamins
40 ug/mL L-tryptophan, 0.5 ug/mL mycobactin J (Allied
Monitor, Fayette, Mo.), and 0.05% Tween 80. Escherichia
coli DH5C. cells, used as cloning hosts were grown on Luria
Bertani (LB) agar or broth supplemented with 50 ug/mL
kanamycin. The conditionally replicating (temperature sen
sitive) recombinant mycobacteriophage phaE94 (Bardarov
et al., Proc. Natl. Acad. Sci. USA, 94:10961-10966, 1997)
used to deliver the transposon Tn5367 (McAdam et al., Infect.
Immun. 63:1004-1012, 1995) was propagated in Mycobacte

rium smegmatis mc 155 at 30° C. as has been described

previously. (Bardarov et al. Proc. Nat. Acad. Sci. USA,
94:10961-10966, 1997). The transposon Tn5367 is a deriva
tive of the insertion sequence IS1096 from M. Smegmatis and
carries the aph gene conferring kanamycin resistance.
45

Example 2
Transposon Mutagenesis
50

M. paratuberculosis cultures were grown to approximately

1.5x10 cfu/mL (OD 0.38-0.75). Cultures (50 mL) were

55

60

1995.

Likewise, monoclonal antibodies can be produced using
well known techniques. In general, immortal antibody pro
ducing cell lines are created by cell fusion, direct transforma

Also encompassed by the present invention are diagnostic
kits. Such kits can contain probes, primers and/or antibodies
for the detection of polynucleotides or polypeptides identified
by the method of the present invention. The probes, primers
and antibodies may, optionally, incorporate a detection moi
ety such as those described herein. The kits may further
comprise buffers, reagents and instructions necessary for the
use of the contents of the kits to detect the presence of the
polynucleotides and/or polypeptides.

65

concentrated by centrifugation and resuspension in 1 mL of
MP buffer (50 mM Tris-HCL, pH 7.6, 150 mL NaCl, 2 mM
CaCl). Bacterial cells and phage were incubated at a non
permissive temperature (37°C.) at the ratios and for the times
indicted in Table 1. After completion of the adsorption time,
2 mL of prewarmed stop buffer (MPbuffer containing 20 mM
sodium citrate and 0.2% Tween 20) was added to prevent
further phage infections. Kanamycin resistant (kan'olonies
were selected on complete growth medium without Tween
plus 15 g/Lagar containing 50 ug/mL, kanamycin at 37°C. In
five independent experiments, 5,620 transductants were
obtained (Table 1). In further experiments, the number of
transductants was increased to 13,526. This provides a rep
resentation of approximately 95% of the genome. Probability
(%) values for the representation of the mutant pool were
calculated using the formula ln(1-P)=Nxln(1-1/4500)
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assuming a genome size of 5.0 Mb (allowing a 5% underes
timation error for the reported size) and 4500 target genes and
where N=13479 for P=95%.

To verify that transposition events had occurred in these
mutants, genomic DNA was isolated using standard tech
niques (Sambrook et al., Molecular Cloning, 2nd ed., Cold
Spring Harbor Press, 1989) and digested with PstI which does
cleave the transposon. The digests were then hybridized over
night understringent conditions of 65°C. in Rapid-hybbuffer
(Amersham-Pharmacia, Piscataway, N.J.) using radiolabeled
plasmid pYUB285 which carries the transposon as a probe
followed by two, 20 minute washes in 2xSSC at 28°C., a 15

5

(10 ml at a cell density of 2x10 CFU/mL) were placed in

10

minutes washin 0.5xSSC at 65° C. and a final 15 minute wash

in 0.1 xSSC at 65° C. Each mutant gave, as expected, one
hybridizable band with at least four distinct sizes observed
(FIG. 1). This confirmed that transpositions had occurred and
that each transformant represented transpositions at different
chromosomal locations. Furthermore all mutants gave the
same pattern of IS900 hybridizable bands as expected for
derivatives of strain K-10, and none of the samples hybridized
with TM4 DNA indicating that hybridization was not due to
the residual presence of vector phage DNA.
Example 3

15

25

mid DNA was isolated from selected transformants and sub

jected to automated sequencing using the BigDye Terminator
Cycle Sequencing Ready Reaction (Perkin Elmer) and the
ABI Prism 310 Genetic Analyzer (Perkin Elmer). Chromo
Somal DNA sequences at the junctions of the transposon
insertions were obtained by cycle sequencing outward from
the transposon using the primers 5'-GGTCAGCGCAGGC
GAAGCCC (BETH-F, SEQID NO: 1) and 5'-GCCAGGTC
CACACTGCCCCC (BETH-R, SEQ ID NO: 2). The results
are shown in FIG. 2. An 8 by duplication was observed at the
transposon-chromosomal junction (SEQ ID NOS: 3 & 4)
(FIG. 2). This duplication was also reported by Pelicic et al.
(Proc. Natl. Acad. Sci. USA, 94:10955-10960, 1997) for
transpositions of this element into five different genes in M.
bovis BCG. The nucleotide sequence derived from BETH-F
was translated based on the mycobacterial codon usage. A
BLAST search identified the chromosomal gene carrying the
transposon insertion as homologous to the M. leprae XerC
gene (GenBank No. Z97369; SEQ 113 NO: 6) encoding a
putative integrase/recombinase (52% identity and 63% simi
larity for the region sequenced, see FIG. 2).

sterile tissue culture flasks, and antibiotics were added at the

following final concentrations Bay y 3118: 0.075 ug/mL
(5xMIC) and 0.3 g/mL (20xMIC); D-cyloserine: 125ug/mL
(5xMIC) and 500 ug/mL (20xMIC); amikacin: 10 ug/mL
(5xMIC), and 40 ug/mL (20xMC). These cultures and a
control without antibiotics (0x) were incubated at 37° C. and
appropriate dilutions were plated in triplicate onto complete
Middlebrook 7H9 medium at various time points. When these
cells were inoculated into complete Middlebrook medium
(growing conditions), they displayed normal growth (growth
control). For growing conditions, cells were treated as
described except that the growth control (Ox) was diluted 1:10
and all cells were washed and resuspended in complete
medium instead of MSS. The cells were also inoculated into

Subcloning and DNA Sequencing
Chromosomal DNA from transposon mutant GPM207 and
pACYC184 vector DNA was digested with EcoRI, ligated
into the corresponding EcoRI site in the paCYC184 vector
and transformed into E. coli DH5O. cells by using standard
methods (Ausubel et al., Short Protocols in Molecular Biol
ogy, 3rd ed., Wiley 1995). E. coli were cultured as described
above and kanamycin resistant transformants isolated. Plas

16
medium containing mycobactin J as described above to an
optical density (ODoo) of 0.3 to 0.4. For non growing con
ditions, cells (200 ml) were harvested at room temperature,
washed in MSS (Middlebrook 7H9 salt solution: 1.0 g/L
KHPO, 0.05 g/L MgSO. NHSO, 2.5 g/L NaHPO,
0.0005 g/L CaCl, 0.001 g/L ZnSO and 0.001 g/L CuSO),
and resuspended in MSS as a single-cell suspension (Will
iams et al., J. Clin. Microbiol. 37:304-309, 1999). Aliquots

30

MSS (no-growth control).
The results are shown in FIG.3 and show that Bay y 3118
at 5x the MIC does not kill non growing bacteria, but has a
bactericidal action on growing bacteria. At both 5x and 20x
the MIC, D-cycloserine had a moderate bactericidal effect on
both growing and non growing bacteria. Amikcin, as
expected, was bactericidal for both growing and non growing
bacteria, but bacteria in stasis were particularly more Suscep
tible.

Example 5
35

Susceptibility of Growing and Non-Growing
Populations of M. paratuberculosis in Macrophage
Culture to Antimicrobial Agents
40

Bovine macrophages of the BOMAC line (Stabel and Sta
bel, Vet. Immunol. Immunopathol. 45:211-220, 1995) are
infected with single-cell Suspensions of mutated bacteria as
described in Example 4 at a MOI of 10:1. Infected BOMAC

45

medium containing Bayy 31 18 at 5x the MIC for three days.
After the incubation period, the infected BOMAC cells are
lysed with 0.25% SDS and the viable bacteria recovered by
centrifugation. These bacteria are used to infect a fresh cul
ture of BOMAC cells, and this procedure is repeated until
each pool of mutants has been passed 3 times through
BOMAC cells. The bacteria recovered from the final passage
and sample from earlier passages are then Subjected to
molecular characterization as described in Example 3.
Example 6

cells are then incubated at 39°C. in RPMI-1640 tissue culture

50

55

Example 4

Virulence Testing of M. paratuberculosis in
Susceptible Mice

Susceptibility of Growing and Non-Growing
Populations of M. paratuberculosis in Broth Culture
to Antimicrobial Agents

60

Antimicrobial agents (antibiotics) tested were the fluoro
quinolone Bay y 3118, and D-cycloserine. The aminoglyco
side amikacin which kills both growing and non-growing M.
paratuberculosis, was included as a control. M. paratubercu
losis strain K-10 was grown in complete Middlebrook 7H9

65

Groups of 6 to 8 week old beige mice were infected orally
with non mutated (wildtype) M. paratuberculosis strain K-10
and euthanized at various times post infection. Bacterial loads
in liver, spleen and ileum were determined. Intestinal wall
tissue was fixed and stained with hematoxylin and eosin for
histological assessment. Mice were given either a high infec
tious dose of 5 doses of 1x10 bacteria administered on alter

nate days (Experiment I) or a low infectious dose of 1x10'
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bacteria in a single dose (Experiment II). The results are given
in Table 2. With the high infectious dose, the bacteria contin
ued to grow in the spleen during the 8-week period but bac

18
organism and a positive control group that receives the non
mutated parental (wild type) strain from which the mutated
organisms are derived. At various times after inoculation,
terial load in the liver leveled off at three weeks. Effective
animals are euthanized and bacterial loads in liver, spleen and
multiplication during the 8-week period was also observed in 5 ileum are determined as described in Example 6. Mutant
the terminal ileum with an in vivo generation time of about strains which do not show continued multiplication in tissues
one week. These results showed that M. paratuberculosis can as compared to the corresponding controls are considered to
infect beige mice through the intestinal mucosa. A higher be non-virulent.
multiplication in the liver and spleen as compared to the
ileum, however, indicated that the mice were experiencing a 10

Example 8

systemic infection. Thus, using the high infectious dose,

-

mice infected with M. E. did not parallel
Screening of Mutant Bacteria for Ability to
all the features of ruminant paratuberculosis. Under the conStimulate Immunity
ditions of Experiment II, the ileum displayed the greatest
bacterial
El multiplication Red in three is Mutant bacteria which have been found to be non virulent
organs for the 8-week period. Thus, using a lower dose, oral by the method of Example 7 are tested tO determine their
infection of beige mice with M. paratuberculosis followed a ability to stimulate immunity against subsequent infection
course similar to the more time consuming monoassociated with non-mutated, virulent strains. Beige 1Ca inoculated
nude mouse intragastric model (Hamilton et al., Vet Pathol.

28:146-155, 1991).

orally with mutant non-virulent strains as described in

2O Example 6. A second group of mice acts as a control group
and receives only vehicle. At various times after inoculation,
mice are challenged with 1x10" bacteria of the non-mutated

Example 7

virulent parental strain. At various times after challenge mice
are euthanized and bacterial loads in liver, spleen and ileum
as are determined as described in Example 6. Mutated strains
which are found to confer immunity are further tested to
Beige mice are inoculated orally with a single dose of determine optimal dosage rates and methods of immuniza
Virulence Tested of Mutated Bacteria in Susceptible
Mice

1x10" bacteria as described in Example 6. For each mutant

tion, for example, single or multiple administration oral ver

tested there is a test group of mice that receives the mutated

Sus parenteral administration.
TABLE 1
Ads

ODoo

Expt.

Ration

culture? PhB

Time

Transd.

Transp

Kan

(hours)

Freq.

Freq

mutants'

I

O48

2O

4

II
III
IV
V

O48
O.38
O.38
0.75

200
25
25
350

4
6
24
4

P

N

value

5.4x 108 1.0 x 10

1344

1344,

26%

5.1 x 10'
7.0 x 10
5.4 x 10
1.1 x 10'

1275
176
136
2689

2619
279S
2931
5620

42%
46%
48%
71%

9.8 x 107
1.8 x 107
1.4 x 107
3.6 x 10

'Experiment number
*OD600m of M. paratuberculosis at harvest
Ratio of phAE94PFU at 30°C. to the number of M. paratuberculosis K-10 CFU
Adsorption time in hours at 37°C.

Transduction frequency: number ofkanamycin-resistant colonies obtained at 37°C, perinfectingphage particle,
Transposition frequency: number of kanamycin-resistant colonies obtained at 37°C, per recipient cell.
"Total number of kanamycin-resistance colonies obtained at 37°C. (putative transposon mutants)
Cumulativee number of kanamyucin-resistant colonies obtained
'Probability (%) value for the representation of the mutant pool assuming randon transposition,

TABLE 2

CFU g (mean of all mice in group it SEM
Spleen

Liver
Week

I

II

5.9 + 0.6 x 10' 7.9 + 0.4 x 10'
1.4 + 0.8 x 10 1.5 + 0.5 x 10'
2.5 + 0.4 x 10
Not done
Not done
3.Ov0.2 x 10?
2.9 + 0.6 x 10 1.1 + 0.6 x 10

I

Ileum
II

2.7+ 0.3 x 107 1...6+ 0.3 x 10°
1.1 + 0.4 x 108 1.8 + 0.4 x 10?
1.7 + 0.5 x 108
Not done
Not done
1...6+ 0.3 x 10°
5.6+ 0.4 x 10 5.9 + 0.4 x 10

I

II

3.5 + 0.6 x 10' 5.9 + 0.6 x 10
4.0 + 0.3 x 10' 2.2 + 0.2 x 10'
9.9 + 0.6 x 10'
Not done
Not done
2.5 + 0.2 x 10'
2.2 + 0.3 x 10 1.3 + 0.3 x 10'
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CONCLUSION

In light of the detailed description of the invention and the
examples presented above, it can be appreciated that the
several aspects of the invention are achieved.
It is to be understood that the present invention has been
described in detail by way of illustration and example in order
to acquaint others skilled in the art with the invention, its
principles, and its practical application. Particular formula
tions and processes of the present invention are not limited to
the descriptions of the specific embodiments presented, but
rather the descriptions and examples should be viewed in
terms of the claims that follow and their equivalents. While

10

20
Some of the examples and descriptions above include some
conclusions about the way the invention may function, the
inventors do not intend to be bound by those conclusions and
functions, but put them forth only as possible explanations.
It is to be further understood that the specific embodiments
of the present invention as set forth are not intended as being
exhaustive or limiting of the invention, and that many alter
natives, modifications, and variations will be apparent to
those of ordinary skill in the are in light of the foregoing
examples and detailed description. Accordingly, this inven
tion is intended to embrace all such alternatives modifica

tions, and variations that fall within the spirit and scope of the
following claims.

SEQUENCE LISTING
<16 Os NUMBER OF SEO ID NOS: 6
<21 Oc
<211
<212>
<213>
<22 Os
<223>

SEO ID NO 1
LENGTH: 2O
TYPE: DNA

ORGANISM: Artificial
FEATURE;

OTHER INFORMATION: Primer

<4 OOs SEQUENCE: 1

ggit cagcgca gg.cgaag.ccc
SEO ID NO 2
LENGTH: 2O
TYPE: DNA

ORGANISM: Artificial
FEATURE;

OTHER INFORMATION: Primer

<4 OOs SEQUENCE: 2

gcc aggt cca cactgcc ccc
<21 Os SEQ ID NO 3
&211s LENGTH: 19
&212s. TYPE: DNA

<213> ORGANISM: Mycobacterium smegmatis
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (1) . . (19)
<223> OTHER INFORMATION: Transposon
<4 OOs SEQUENCE: 3

tgttaacggg ct ctitcgca

19

<21 Os SEQ ID NO 4
&211s LENGTH: 19
&212s. TYPE: DNA

<213> ORGANISM: Mycobacterium smegmatis
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (1) . . (19)
<223> OTHER INFORMATION: Transposon
<4 OOs SEQUENCE: 4

tgcgaagagc ctgttaacg
<21 Os SEQ ID NO 5
&211s LENGTH: 23
212s. TYPE: PRT

<213> ORGANISM: Mycobacterium paratuberculosis

19
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22
- Continued

<4 OOs, SEQUENCE: 5

Arg Arg Thr Gly Pro Val Gly Ile Ser Ala Val Ala Ala Lieu. His Gly
1.

5

1O

15

Trp Ser Asp Ser Gly Glin Pro
2O

SEQ ID NO 6
LENGTH: 23
TYPE PRT

ORGANISM: Mycobacterium leprae
<4 OOs, SEQUENCE: 6

Glin Arg Thr Ala Pro Phe Gly Val Pro Ala Ala Asp Ala Lieu. Arg Gly
1.

5

1O

15

Trp Lieu. Asp Asp Gly Arg Pro
2O

What is claimed and desired to be secured by Letters Patent

5. The method of claim 1, wherein said antimicrobial is

D-cycloserine.

is a follows:

1. A method for isolating a bacteria comprising:
introducing at least one mutation into the genome of a

25

virulent bacteria;

7. The method of claim 1, wherein said mutation is a

culturing the mutated bacteria in the presence of an anti
microbial agent that kills growing but not non-growing
bacteria;

random mutation.
30

Selecting Surviving bacteria;
testing the selected surviving bacteria for virulence; and
Selecting attenuated mutant bacteria.
2. The method of claim 1, wherein said bacteria is a myco
bacteria.

3. The method of claim 1, wherein said antimicrobial agent
is a fluoroquinolone.
4. The method of claim 3, wherein said fluoroquinolone is
Bay y 31 18.

6. The method of claim 1, wherein said mutation is intro

duced by insertion of a transposon.

35

8. A composition consisting of an attenuated mutant bac
teria selected by the method of claim 1, said composition
capable of stimulating an immune response against a disease
caused by the virulent bacteria.
9. The composition of claim 8, further comprising a phar
maceutically acceptable carrier, diluent or excipient.
10. The composition of claim 8, wherein said bacteria is a
mycobacteria.

